MIAMI, February 18, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2024 financial results ...

Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating.Light Up your Portfolio with Spark:Easily identify ...

Summit Therapeutics (NASDAQ:SMMT) traded higher in the premarket on Wednesday after Citi upgraded the stock to Buy from Neutral, becoming the latest brokerage to issue a bullish view on the cancer ...

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Shares of Summit Therapeutics (NASDAQ:SMMT) gained in the premarket on Friday after Cantor Fitzgerald became the latest to initiate its coverage with a bullish view, citing the potential of its ...

1 Day SMMT -1.36% DJIA -1.69% S&P 500 -1.97% Health Care/Life Sciences 0.11% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...